Pasireotide
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-PASIREOTIDE |
|---|---|
| Type | Drug |
| Aliases | SigniforSignifor LARПасиреотид |
| Status | reviewed 2026-07-11 | pending_clinical_signoff |
| Diseases | DIS-PITUITARY-ADENOMA |
| Sources | SRC-NCCN-CNS-2025 |
Drug Facts
| Class | Somatostatin analogue (multi-receptor SSTR1/2/3/5, high SSTR5 affinity) |
|---|---|
| Mechanism | Cyclohexapeptide somatostatin analogue binding SSTR1, SSTR2, SSTR3, and particularly SSTR5 — the receptor subtype most highly expressed on corticotroph adenomas — distinguishing pasireotide from the largely SSTR2-selective first-generation SSAs (octreotide, lanreotide). Suppresses ACTH secretion from corticotroph adenomas (Cushing disease) and, via SSTR2/SSTR5, GH/IGF-1 secretion from somatotroph adenomas (acromegaly), including tumors with an inadequate response to first-generation SSA. Two formulations: subcutaneous (short-acting, Cushing disease) and long-acting release (LAR, intramuscular monthly — acromegaly and surgery-ineligible/persistent Cushing disease). |
| Typical dosing | Cushing disease: pasireotide SC starting dose 0.6 mg subcutaneously twice daily, titrated per cortisol response and tolerability (product-label range approximately 0.3-0.9 mg SC BID); long-acting pasireotide LAR 10 mg IM every 4 weeks is an alternative for Cushing disease not amenable to surgery, titrated per response. Acromegaly: pasireotide LAR starting dose 40 mg IM every 4 weeks, titrated up to 60 mg IM q4w per IGF-1 response, typically reserved for inadequate response to first-generation SSA (octreotide/lanreotide). Confirm exact titration schedule with treating endocrinology team. |
| Ukraine registered | False |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-07-11 |
Notes
STUB pending clinical co-lead signoff (CHARTER §6.1 — dev-mode-exempted, safe to merge as draft content, not published/verified clinical advice). Pasireotide is the medical option named in the Disease narrative for Cushing disease and is also listed among acromegaly SSA options. Modeled here as a single Drug entity covering both SC (Cushing) and LAR (acromegaly + surgery-ineligible Cushing) formulations, consistent with how this KB models other multi-formulation drugs. Steroidogenesis inhibitors named alongside pasireotide in the Cushing narrative (ketoconazole, metyrapone, osilodrostat) are not separately authored as Drug entities in this pass — see DIS-PITUITARY-ADENOMA proposal notes.
Used By
Indications
IND-PITUITARY-ADENOMA-1L-ACROMEGALY-SURGERY-SSA- IND-PITUITARY-ADENOMA-1L-ACROMEGALY-SURGERY-SSAIND-PITUITARY-ADENOMA-1L-CUSHING-SURGERY-MEDICAL- IND-PITUITARY-ADENOMA-1L-CUSHING-SURGERY-MEDICAL
Regimens
REG-PASIREOTIDE-CUSHING- Pasireotide for Cushing disease (pituitary-directed medical therapy)REG-SSA-ACROMEGALY- Somatostatin analogue for acromegaly (lanreotide first-generation SSA; pasireotide for SS...